EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy

Jason A Roberts iD, Marta Ulldemolins, Xin Liu, João P Baptista, Irma Bilgrami, Clement Boidin, Alexander Brinkmann, Pedro Castro, Gordon Choi, Louise Cole, Jan J De Waele, Renae Deans und 48 weitere

Intensive Care Medicine · 2025-09 · 51 (9) · 1628-1640

DOI: 10.1007/s00134-025-08067-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Intensive Care Medicine, online erschienen am 13.08.2025. Verfasst von Jason A Roberts und 59 weiteren Autor:innen. Beteiligte Einrichtung: University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women's Hospital Campus,…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Critical Illness, Meropenem, Piperacillin, Tazobactam Drug Combination. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, Research Grants Council of the Hong Kong Special Administrative Region, China, The University of Queensland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCritical IllnessMeropenemPiperacillin, Tazobactam Drug CombinationRenal Replacement TherapyAgedFemaleHumansMaleMiddle AgedIntensive Care UnitsMonte Carlo MethodProspective Studies

Stichwörter der Autor:innen

Critically ill patientsDosing nomogramsMeropenemPharmacokineticsPiperacillin/tazobactamRenal replacement therapy

Substanzen

Anti-Bacterial AgentsMeropenemPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women's Hospital Campus, Herston, Brisbane, Australia. j.roberts@uq.edu.au.
  • Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia. j.roberts@uq.edu.au.
  • Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Australia. j.roberts@uq.edu.au.
  • Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia. j.roberts@uq.edu.au.
  • Division of Anesthesia Critical Care, Pain and Emergency Medicine, Nîmes University Hospital, UR-UM103 IMAGINE, Universite Montpellier, Montpellier, France. j.roberts@uq.edu.au.
  • University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women's Hospital Campus, Herston, Brisbane, Australia.

ORCID-Profile: Jason A Roberts

Förderung

  • National Health and Medical Research Council
  • Research Grants Council of the Hong Kong Special Administrative Region, China
  • The University of Queensland

Zitieren

APA

Roberts, J. A., Ulldemolins, M., Liu, X., Baptista, J. P., Bilgrami, I., Boidin, C., Brinkmann, A., Castro, P., Choi, G., Cole, L., De Waele, J. J., Deans, R., Donnellan, S., Eastwood, G. M., Frey, O. R., Goutelle, S., Gresham, R., Jamal, J. A., Joynt, G. M., …, & Wittebole, X. (2025). Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy. Intensive Care Medicine, 51(9), 1628-1640. https://doi.org/10.1007/s00134-025-08067-w

Vancouver

Roberts JA, Ulldemolins M, Liu X, Baptista JP, Bilgrami I, Boidin C, et al. Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy. Intensive Care Medicine. 2025;51(9):1628-1640. doi:10.1007/s00134-025-08067-w

BibTeX
@article{Roberts2025,
  author = {Roberts, Jason A and Ulldemolins, Marta and Liu, Xin and Baptista, João P and Bilgrami, Irma and Boidin, Clement and Brinkmann, Alexander and Castro, Pedro and Choi, Gordon and Cole, Louise and De Waele, Jan J and Deans, Renae and Donnellan, Sine and Eastwood, Glenn M and Frey, Otto R and Goutelle, Sylvain and Gresham, Rebecca and Jamal, Janattul Ain and Joynt, Gavin M and Kanji, Salmaan and Kluge, Stefan and König, Christina and Koulouras, Vasilios P and Lassig-Smith, Melissa and Laterre, Pierre-Francois and Lee, Anna and Lefrant, Jean-Yves and Lei, Katie and Leung, Patricia and Llaurado-Serra, Mireia and Martin-Loeches, Ignacio and Nor, Mohd Basri Mat and Mudaliar, Yugan and Ostermann, Marlies and Paul, Sanjoy K and Peake, Sandra L and Rello, Jordi and Roberts, Darren M and Roberts, Michael S and Richards, Brent and Rodríguez, Alejandro and Roehr, Anka C and Roger, Claire and Seoane, Leonardo and Sinnollareddy, Mahipal and Sousa, Eduardo and Soy, Dolors and Spring, Anna and Starr, Therese and Stephens, Dianne and Taccone, Fabio Silvio and Thomas, Jane and Turnidge, John and Valkonen, Miia and Varghese, Julie M and Wallis, Steven C and Walker, Robert J and Williams, Tricia and Wilson, Luke C and Wittebole, Xavier},
  title = {Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy},
  journal = {Intensive Care Medicine},
  year = {2025},
  volume = {51},
  number = {9},
  pages = {1628--1640},
  doi = {10.1007/s00134-025-08067-w}
}
Kostenlos starten →